首页 > Autophagy > EGFR
EGFR
T0078 Lapatinib Lapatinib(GW-572016) is an effective ErbB2 and EGFR inhibitor with IC50 of 9.2 and 10.8 nM, respectively.
T0078L Lapatinib ditosylate monohydrate Lapatinib is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors. Lapatinib therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury.
T0129 Sanguinarine chloride Sanguinarine chloride, a benzophenanthridine alkaloid, stimulates apoptosis by activating the production of reactive oxygen species (ROS).
T0373 Erlotinib Erlotinib (NSC 718781; OSI-744; R1415) is an EGFR inhibitor (IC50 of 2 nM). It is >1000-fold more sensitive for EGFR than human v-Abl or c-Src.
T0373L Erlotinib hydrochloride Erlotinib is a direct acting inhibitor against human EGFR tyrosine kinase (IC50: 2 nM). Erlotinib hydrochloride (trade name Tarceva) is a drug used in the treatment of pancreatic Y, non-small cell lung Y and some other types of Y.
T1144L Lidocaine Hydrochloride hydrate Lidocaine Hydrochloride hydrate is an amide local anesthetic, has anti-inflammatory property.
T1656 Vandetanib Vandetanib is a Kinase Inhibitor.
T1737 Genistein Genistein is an isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA TOPOISOMERASES, TYPE II), with antineoplastic and antitumor activities.
T1761 PD153035 hydrochloride PD153035 hydrochloride (ZM 252868; AG 1517) is a effective and selective inhibitor of EGFR (Ki: 5.2 pM, IC50: 29 pM); few influence against FGFR, PGDFR, InsR, CSF-1, and Src.
T1773 Afatinib (BIBW2992) Dimaleate Afatinib is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.
T1985 WHI-P154 WHI-P154 is a potent JAK3 inhibitor.
T1991 ZM323881 hydrochloride ZZZM 323881 hydrochloride is a potent and selective VEGFR2 inhibitor.
T2032 WHI-P180 WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
T2035 WHI-P258 WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3. This compound binds JAK3 weakly and may be used as a JAK-binding negative control in the development of new therapeutics.
T2041 AG-1517;PD153035 PD153035 hydrochloride is an effective and selective inhibitor of EGFR (Ki/IC50: 5.2/29 pM, in cell-free assays); little inhibitory against FGFR, PGDFR, InsR, CSF-1 and Src.
T2047 AG-1478 AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor.
T2055 WS3 WS3, a β cell proliferation inducer, regulates Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.
T2063 AG 18 AG-18 inhibits EGFR with IC50 of 35 μM.
T2106 WS6 WS6, a β cell proliferation inducer, regulates Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.
T2116 AEE788 AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
T2245 CL-387785 (EKI-785) CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR(IC50: 370+/-120 pM); is able to overcome resistance caused by the T790M mutation on a functional level.
T2280 Endoxifen Z-isomer Endoxifen (EDX) is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptors that also inhibits aromatase activity.
T2303 Afatinib (BIBW2992) Afatinib is a tyrosine kinase receptor inhibitor that is used in the therapy of selected forms of metastatic non-small cell lung cancer.
T2307 Icotinib Hydrochloride Icotinib Hydrochloride is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-me
T2325 Neratinib Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor (IC50: 59/92 nM) for HER2 and EGFR, respectively. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocke
T2327 Pelitinib Pelitinib (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
T2364 Irbinitinib Irbinitinib(ARRY-380; ONT-380) is a potent and selective HER2 inhibitor (IC50: 8 nM).
T2369 CO-1686 Rociletinib is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity.
T2446 KI8751 KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
T2460 ZM 39923 hydrochloride ZM 39923 hydrochloride is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.
T2479 Tyrphostin A9 Tyrphostin 9 is an Agricultural acaricide, now superseded. Tyrphostin 9 is firstly designed as an EGFR inhibitor
T2483 Dacomitinib (PF299804, PF299) Dacomitinib(PF299804; PF-00299804) is a highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with IC50 of 6, 45.7 and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
T2490 AZD-9291 Osimertinib is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC).
T2491 AZ5104 AZ5104 is a potent EGFR inhibitor.
T2501 Canertinib dihydrochloride Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities.
T2518 ARRY-380 ARRY-380 is a potent and selective HER2 inhibitor.
T2600 AG-490 AG-490 (Tyrphostin AG 490) is an inhibitor of EGFR (IC50: 0.1 μM). It is 135-fold more selective for EGFR than ErbB2, also inhibits JAK2 with no effect to Lyn, Lck, Syk, Btk, and Src.
T2642 PD173074 PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for FGFR1 than PDGFR and c-Src.
T2705 Mutant EGFR inhibitor Mutant EGFR inhibitor is a selective and potent Mutated EGFR inhibitor, inhibits L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant.
T2851 Daphnetin Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor with inhibitory for EGFR (IC50: 7.67 μM), PKA (IC50: 9.33 μM), and PKC (IC50: 25.01 μM), also exhibit anti-oxidant and anti-inflammatory activities.
T2859 Biochanin A Biochanin A is an isoflavone derivative isolated from red clover Trifolium pratense with anticarcinogenic properties. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor.
T2959 Ginsenoside Rh2 Ginsenoside Rh2, an extract of red Panax ginseng, is a potent anti-inflammatory and anticancer drug.
T2995 Chrysophanic Acid Chrysophanic acid is an EGFR/mTOR pathway inhibitor, which can be found in rhubarb, and sorrel.
T3024 Avitinib Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, incl
T3059 AP26113 Brigatinib is a excellently effective and specific ALK inhibitor( IC50 =0.6 nM).
T3108 CUDC-101 CUDC-101 is a potent inhibitor of HDAC, EGFR and HER2 with IC50s of 4.4, 2.4 and 15.7 nM, respectively.
T3192 NS1643 NS1643 is a potent human ether-a-go-go related gene (hERG) KV11.1 channel activator with EC50 of 10.5 μM.
T3402 Ginsenoside Rg3 Ginsenoside Rg3 possess an ability to inhibit the lung metastasis of tumor cells via inhibition of the adhesion and invasion of tumor cells. It inhibits the proliferation of human umbilical vein endothelial cells(HUVEC) and has anti-angiogenesis activities.
T3506 EGF816 Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity over wild type (wt) EGFR in vitro.
T3545 RG 13022 RG13022 is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor (IC50: 4 μM).
T3558 EBE-A22 EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.
T3621 Brigatinib Brigatinib is a highly potent and selective ALK inhibitor.
T3634 AZD-9291 mesylate AZD-9291 mesylate is an irreversible and mutant-selective EGFR inhibitor.
T3659 AZD3759 AZD3759 is an orally active, effective and central nervous system-penetrant EGFR inhibitor. The IC50 values were 0.2, 0.3 and 0.2 nM for EGFR L858R mutant, TK wild-type, and Exon 19Del enzymes, respectively.
T3721 Avitinib maleate Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (EGFR) inhibitor.
T3870 Cyasterone Cyasterone, a natural EGFR inhibitor, can inhibit the growth of A549 and MGC823 cells, via regulating EGFR signaling pathway, it may be a promising anti-cancer agent. Cyasterone has antifeeding activity.
T4014 CP-724714 CP-724714 is an effective and selective HER2/ErbB2 inhibitor (IC50: 10 nM), >640-fold selectivity against EGFR, Abl, InsR, PDGFR, IRG-1R, Src, VEGFR2, c-Met etc.
T4183 lavendustin A lavendustin A is a potent, cell-permeable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.
T4205 AG 494 AG-494 is an inhibitor of epidermal growth factor receptor kinase.
T4249 AZD3759 hydrochloride AZD3759 (hydrochloride) is an effective, orally active and central nervous system-penetrant?EGFR?inhibitor. At Km?ATP concentrations, the?IC50s are 0.2/0.3/0.2 nM for EGFR (L858R)/EGFR (wt)/EGFR (exon 19Del).
T4296 MTX-211 MTX-211, an inhibitor of EGFR and PI3K, is used for the therapy of cancer and other diseases.
T4326 Tyrphostin AG 555 AG 555 is an EGFR tyrosine kinase inhibitor.
T6008 CNX-2006 CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.
T6036 Brivanib Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3.
T6039 TAK-285 TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.
T6046 CP-724714 CP-724,714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc. Phase 2.
T6078 Saracatinib Saracatinib (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to c-Yes, Lyn, Fyn, Fgr, Blk and Lck; less active for Abl and EGFR (L858R and L861Q).
T6092 AZD8931 (Sapitinib) AZD8931, a reversible, ATP competitive inhibitor of EGFR(IC50=4 nM), ErbB2(IC50=3 nM) and ErbB3(IC50=4 nM), is more effective over Gefitinib or Lapatinib against NSCLC cell, 100-fold more specific for the ErbB family over MNK1 and Flt.
T6124 Mubritinib (TAK 165) Mubritinib (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM.
T6136 Canertinib (CI-1033) Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
T6153 Icotinib Icotinib is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity.
T6196 PP1 PP1, a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
T6227 Benidipine hydrochloride Benidipine HCl, a hydrochloride salt form of benidipine, is used as a blocker of dihydropyridine calcium channel.
T6235 Lapatinib (GW-572016) Ditosylate Lapatinib Ditosylate, an effective EGFR and ErbB2 inhibitor, is with IC50 of 10.8 and 9.2 nM for EGFR and ErbB2, respectively.
T6238 WZ4002 WZ4002 is a mutant-selective EGFR inhibitor for EGFR(L858R) and EGFR(T790M) with IC50 of 2 nM/8 nM.
T6266 PP2 PP2 is a effective inhibitor of Lck/Fyn (IC50:4/5 nM) , ~100-fold less potent to EGFR, inactive for ZAP-70, PKA and JAK2.
T6328 Desmethyl Erlotinib OSI-420 is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).
T6331 AST-1306 AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, respectively.
T6427 Butein Butein, a plant polyphenol, is isolated from Rhus verniciflua. It can inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, and also can inhibit EGFR.
T6619 OSI-420 OSI-420 (Desmethyl Erlotinib,CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for? human EGFR and EGFR autophosphorylation in tumor cells.
T6712 Tyrphostin AG 879 Tyrphostin AG 879 effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.
T6733 WZ3146 WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I).
T6734 WZ8040 WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).
T6824 EAI045 EAI045, an allosteric inhibitor, targets towards drug-resistant EGFR mutants but avoids the wild-type receptor.
T6918 Olmutinib (HM61713, BI 1482694) Olmutinib is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is select
T6932 PD168393 PD168393 is an irreversible EGFR inhibitor (IC50: 0.70 nM), irreversibly alkylate Cys-773; inactive against PKC, FGFR, PDGFR, and insulin.
T4185 lavendustin C Lavendustin C is a potent inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase.
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科研,我们不为任何其他用途提供产品和服务